Avoid common mistakes on your manuscript.
Correction: Breast Cancer https://doi.org/10.1007/s12282-023-01451-8
The article “Adjuvant olaparib in the subset of patients from Japan with BRCA1‑ or BRCA2‑mutated high‑risk early breast cancer from the phase 3 OlympiA trial”, written by Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer Jr, Andrew Tutt, was originally published electronically on the publisher’s internet portal on 01 April 2023 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 20 April 2023 to © The Author(s) 2023 and the article is forthwith distributed under a Creative Commons Attribution4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Yamauchi, H., Toi, M., Takayama, S. et al. Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer 30, 606 (2023). https://doi.org/10.1007/s12282-023-01468-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12282-023-01468-z